All the news Showing 10 of 33 articles from: EASL 2015Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Genotype 4 Sofosbuvir/ledipasvir cures more than 90% of people with hepatitis C genotypes 4 and 5 Liz Highleyman / 20 May 2015 An interferon-free regimen of sofosbuvir and ledipasvir (Harvoni) produced sustained virological response rates of 93% for people with HCV genotype 4 and 95% for those with genotype 5, according to a French study ... Cirrhosis Statin use associated with lower risk of liver decompensation and death in hepatitis C patients with cirrhosis Liz Highleyman / 19 May 2015 People with hepatitis and liver cirrhosis were significantly less likely to progress to decompensated disease and less likely to die if they used statins to control blood cholesterol, according to an analysis of ... Treatment in liver transplanted Civacir immune globulin may help prevent HCV reinfection after liver transplant Liz Highleyman / 18 May 2015 Civacir, a hepatitis C immune globulin or antibody product, reduced the likelihood of hepatitis C virus infecting the new liver graft after transplantation in people who were receiving, but had not yet ... Antiviral therapy Nucleic acid polymer REP 2139-Ca shows promising activity against hepatitis B and hepatitis delta Liz Highleyman / 15 May 2015 The nucleic acid-based polymer REP 2139-Ca lowered hepatitis B surface antigen (HBsAg) levels and significantly reduced hepatitis B and hepatitis delta viral loads when combined with immunotherapy, according to presentations at the European ... Deciding when and how to treat HCV Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients Keith Alcorn / 13 May 2015 Shortening hepatitis C treatment to 6 weeks for easier-to-treat patients without cirrhosis does not greatly reduce the efficacy of hepatitis C treatment for people with genotype 1 infection, according to results of a ... Deciding when and how to treat HCV Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough Liz Highleyman / 13 May 2015 A six-week regimen of sofosbuvir (Sovaldi) plus two experimental direct-acting antivirals being developed by Gilead Sciences cured more than 90% of previously untreated people with genotype 1 hepatitis C virus and no liver ... Hepatocellular carcinoma (HCC) People with hepatitis C have higher cancer rates, even when excluding liver cancer Liz Highleyman / 11 May 2015 Hepatitis C patients in the Kaiser Permanente Southern California health maintenance organisation had significantly increased cancer rates compared to members without HCV infection, researchers reported at the European Association for the Study of ... Cirrhosis Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis Liz Highleyman / 06 May 2015 Interferon-free regimens containing sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured about three-quarters of people with genotype 1 chronic hepatitis C with advanced cirrhosis and MELD scores >10 in the real-world HCV-TARGET study, researchers reported ... Treatment in kidney dialysis Sofosbuvir-based treatment safe and effective in advanced kidney disease Keith Alcorn / 05 May 2015 Sofosbuvir-based direct-acting antiviral therapy for hepatitis C can be used safely and effectively in people with very advanced kidney disease, including people on dialysis, according to the findings of the HCV-TARGET international cohort ... Treatment for previous non-responders & relapsers When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration Liz Highleyman / 05 May 2015 More than 70% of people with chronic genotype 1 hepatitis C who did not achieve a sustained virological response when treated with sofosbuvir/ledipasvir (Harvoni) for 8 or 12 weeks were cured with a ... ← Prev1234Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive